Previous Close | 33.84 |
1-Year Change | 34.13% |
6-Months Change | 17.22% |
3-Months Change | 11.87% |
Moving Avg (50d) | 32.908 |
Moving Avg (200d) | 30.181 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.84B |
Beta (3-Years) | 0.65 |
Revenue Growth (ttm) | -7.35% |
Net Profit Margin (ttm) | 4.2% |
Return On Assets (ttm) | 1.99% |
EPS (ttm) | 0.4 |
PE Ratio (ttm) | 84.6 |
Dividend Yield | % |
Asset Description: | Supernus Pharmaceuticals, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2024-08-15 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
33.163 | 32.148 | 31.471 | 30.456 | 28.764 | 27.072 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Pharmaceuticals |
Country: | United States |